Tim Wesselman

Tim Wesselman

Tim Wesselman is Founder of Rosalind (formerly OnRamp Bio) and CEO since 2013. For the 20 years prior to starting Rosalind, Tim had been dedicated to understanding next-generation servers and storage solutions. Serving as Vice President at Hewlett-Packard, he led strategy & partnerships with the market leaders in big data software, advanced processors and cloud computing. These partners included known names, like FaceBook, MapR, Cloudera and DataStax with solutions that companies like Apple, Amazon, Microsoft, Baidu and many others heavily rely on today. Seeing the opportunity to bring this knowledge of advanced computing technology into the healthcare space, Tim founded and launched Rosalind to empower researchers, doctors and drug developers to accelerate genomic discoveries through collaboration so that we all can realize the promise of precision medicine and unlock biology's greatest unknowns.

Recent posts by Tim Wesselman

4 min read

Tracking the Spread of the COVID-19 Variants

By Tim Wesselman on Jun 29, 2022 12:59:04 PM

The ROSALIND Tracker is a real-time dashboard for the United States rapid genotyping "Project ROSA" program for SARS-CoV-2. This research was supported by the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health as part of the Rapid Acceleration of Diagnostics (RADxˢᵐ) initiative.

Topics: Big Data Rosalind Public Data COVID-19
4 min read

In The News: ROSALIND builds NEW COVID-19 Variant Monitor SYSTEM

By Tim Wesselman on Mar 23, 2021 4:19:53 PM

This new web-based system, developed with NIH funding, will aid in monitoring emerging SARS-CoV-2 variants and the performance of diagnostic tests

Topics: BioInformatics Rosalind Public Data Collaboration COVID-19
3 min read

Our new corporate identity

By Tim Wesselman on Mar 1, 2021 10:35:03 AM

In Her Honor...    

Topics: Rosalind Collaboration Search Intelligence
3 min read

How Knowledge Graphs Shape the Future of Discovery

By Tim Wesselman on Jan 14, 2021 6:15:00 AM

Knowledge Graph architecture unifies information and creates a foundation for FAIR (Findable Accessible Interoperable and Reusable) data management and advanced search capabilities. The impact for research is an exponential expansion and acceleration in extracting insights.

Topics: Rosalind Collaboration Search Intelligence Enterprise
2 min read

Deeper Insights with Gene Set Variation Analysis

By Tim Wesselman on Oct 27, 2020 8:13:36 AM

Opening a new door to discovery, ROSALIND now empowers scientists to explore experiment results by key terms (Pathways, Signatures, Diseases and Drugs) that are significantly enriched across all samples using GSVA scores. You can access Term Exploration within the Discovery and Analysis section of each experiment. ROSALIND has been pre-computing these scores for the past several months, so many existing experiments already have this new analysis ready for exploration.

Every experiment and scientific question seeks to find insights on biological processes and pathways. Prior to now, this scientific journey always began with an exploration of genes to uncover the changes to underlying pathways. Now, you can begin exploring Pathways and significant Terms regardless of comparisons or cut-offs.

Topics: Transcriptome BioInformatics Rosalind Pathways
5 min read

ROSALIND® for nCounter Users

By Tim Wesselman on Oct 8, 2020 7:56:51 AM

October 08, 2020 09:33 AM Eastern Daylight Time
Topics: BioInformatics Rosalind Collaboration NanoString
3 min read

Lexogen Partners for QuantSeq 3' Analysis & Collaboration

By Tim Wesselman on Jun 17, 2020 5:04:17 PM

VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

Topics: BioInformatics Rosalind RNAseq Collaboration
2 min read

Canopy Partners with ROSALIND for Data Analysis & Collaboration

By Tim Wesselman on Jun 17, 2020 3:51:55 PM

St. Louis, MO /PR Newswire/—Canopy Biosciences, a multi-omic CRO providing NanoString® nCounter® and RNA Seq services to both clinical and research customers, has partnered with Onramp BioInformatics™ to offer their ROSALIND™ interactive data analysis platform for Canopy’s gene expression services.  Launched earlier this year, Canopy has been providing this intuitive platform to customers that have run NanoString and RNA Seq projects.

Topics: BioInformatics Rosalind RNAseq Collaboration NanoString
5 min read

NanoString-OnRamp Bio Partnership

By Tim Wesselman on May 21, 2020 7:53:18 PM

NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data

Expanded Functionality to Support COVID-19 Research
Immediately Available Through Early Access

May 20, 2020 09:00 AM Eastern Daylight Time

SEATTLE--()--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a collaboration for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. The new analysis functionality is built into ROSALIND™, OnRamp’s cloud-based analysis suite that facilitates data visualization, exploration and collaboration. The companies are releasing these new capabilities through early access and immediately offering it to COVID-19 researchers performing critical host response studies on the nCounter platform.

Topics: BioInformatics Rosalind Collaboration COVID-19
4 min read

COVID19 Support and Pathway Enhancements

By Tim Wesselman on Apr 15, 2020 11:27:20 AM

 

Topics: BioInformatics Rosalind Public Data Collaboration COVID-19